XL-001

CAS No. 1426153-46-9

XL-001( XL001 )

Catalog No. M11799 CAS No. 1426153-46-9

XL-001 (XL001) is a novel specific CB2 inverse agonist with Ki of 0.5 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    XL-001
  • Note
    Research use only, not for human use.
  • Brief Description
    XL-001 (XL001) is a novel specific CB2 inverse agonist with Ki of 0.5 nM.
  • Description
    XL-001 (XL001) is a novel specific CB2 inverse agonist with Ki of 0.5 nM; inhibits in a dose-dependent fashion the fibrogenic response induced by CB2 overexpression, CB2 agonist or transforming growth factor-β1, ameliorates kidney injury, fibrosis and inflammation in both the obstruction and ischemia/reperfusion models.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    XL001
  • Pathway
    GPCR/G Protein
  • Target
    Cannabinoid Receptor
  • Recptor
    Cannabinoid Receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1426153-46-9
  • Formula Weight
    438.586
  • Molecular Formula
    C25H30N2O3S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CCN(CC)C1=CC=C(C=C1)CN(C2=CC=C(C=C2)C)S(=O)(=O)C3=CC=C(C=C3)OC
  • Chemical Name
    N-(4-(diethylamino)benzyl)-4-methoxy-N-(p-tolyl)benzenesulfonamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Zhou L, et al. Kidney Int. 2018 Aug 6. pii: S0085-2538(18)30397-1.
molnova catalog
related products
  • AM-1235

    AM-1235 is a potent and selective cannabinoid receptor CB1 agonist.

  • AZD1940

    AZD1940 (UNII-0J0035E9FT) is a high affinity CB(1)/CB(2) receptor agonist of the cannabinoid with oral activity. Application in the study of orofacial pain.

  • Anandamide

    Anandamide, an immune modulator, acts via not only cannabinoid receptors (CB1 and CB2) but also other targets (e.g., GPR18/GPR55) in the central nervous system.